Breakthrough in Gene-Editing Therapy for Cholesterol Reduction
Verve Therapeutics has announced encouraging results from its Phase 1b clinical trial of VERVE-102, a gene-editing therapy targeting PCSK9 to lower LDL-C, or “bad,” cholesterol levels. The trial, named Heart-2, demonstrated significant reductions in LDL-C with a favorable safety profile, marking a potential advancement in the treatment of cardiovascular diseases.
Key Findings from the Heart-2 Trial
The Heart-2 trial evaluated VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). Among 14 participants across three dose levels, a single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 protein levels and LDL-C. The mean reduction in LDL-C was 53%, with a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort. These findings highlight the therapy’s potential for deep and durable cholesterol reduction, which is critical for populations at high risk of cardiovascular events.
Safety Profile and Future Development
VERVE-102 was well-tolerated, with no treatment-related serious adverse events (SAEs) reported. No clinically significant laboratory abnormalities were observed. The therapy utilizes a proprietary GalNAc-LNP formulation, which has shown a potentially best-in-class safety profile. Verve Therapeutics plans to report final Heart-2 dose escalation data in the second half of 2025, initiate a Phase 2 clinical trial, and await a decision from Eli Lilly and Company regarding the PCSK9 opt-in.
Implications for Cardiovascular Disease Treatment
Cardiovascular disease remains the leading cause of death globally, with many patients struggling to maintain adherence to conventional cholesterol-lowering therapies. VERVE-102’s one-time treatment approach could offer a transformative solution, reducing the need for lifelong medication. However, further research is needed to confirm long-term efficacy and safety in larger, more diverse populations.
Conclusion
The preliminary results from the Heart-2 trial underscore the promise of gene-editing technologies in addressing unmet medical needs. As Verve Therapeutics advances VERVE-102 through clinical development, stakeholders will be closely monitoring its progress toward regulatory approval and potential commercialization.